Gilead Sciences’ Stock News: Algorithmic And Fundamental Analysis


  • Gilead Sciences has had one of its most successful years, with growth in Q3 2014 exceeding 100% growth over lastGilead year's Q3.
  • Sovaldi currently profits on being the first to market; the single product is currently responsible for almost 50% of the company's revenues.
  • The current product portfolio poses a high risk, and is dependent on competitors' failures/successes in the upcoming months.
  • I Know First algorithmic forecast suggest the stock will increase in the next 3-7 days, but is no longer the optimal long-term investment.

Company Information

Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharmaceutical company that researches, develops and commercializes medicinal products. Focus areas include HIV/AIDS, liver diseases (hepatitis B and C) and cardiovascular/metabolic and respiratory conditions. The company is globally present with operations in North America, Europe, and Asia Pacific. The two major focus areas are antiviral and cardiovascular products, with their flagship products Sovaldi and newly approved Harvoni currently raking in the cash.

Read the full article on Seeking Alpha